NLRP3 and early-onset autosomal dominant Alzheimer disease: These nanovectors enhance the efficacy of glibenclamide by promoting autophagy and reducing NLRP3 activation, illustrating the potential of nanotechnology in treating complex neurodegenerative disorders like Alzheimer’s disease [68].